Vertex Spots Potential Bargain Of $60m Entry Into Complement Regulation
Cash-Strapped Catalyst Bio Forced Into Quick Sale
Vertex has acquired the full assets to a promising protease-based drug platform from Catalyst, broadening its R&D base once again.
You may also be interested in...
ARCH closed a $3bn VC fund to end the month of June while in the same week six public biopharma firms said they are cutting jobs. Even so, some publicly traded companies have been able to launch sizeable offerings, including a $450m note sale by Cytokinetics and Xenon’s $250m follow-on.
Biosimilar licensing agreement also includes option on Yervoy-based product. Oxford BioTherapeutics, ImmunoGen pair their technologies for development of novel cancer ADCs.
The neoantigen immunotherapy company is a casualty of slow R&D progress and a squeeze on biotech finance – and more firms are in the firing line.